Baxalta — Merger or Acquisition (March 2016)
9 slides from Baxalta's merger presentation, Mar 18, 2016
Slide 1: Contents
Contents Guiding principles for organization design L1 organization structure Key governance bodies From-To organization charts Timeline Note: the organizational structure proposed here is conditional on the closing of the Shire-Baxalta transaction, including the related regulatory and shareholder a
Slide 2: Guiding principles for organization design: Integrate to Grow
Guiding principles for organization design: Integrate to Grow We are creating a leading global biotech company built from the best of both Shire and Baxalta; a company uniquely focused on patient and customer centricity We are employing an “inverted pyramid” approach to integration, an approach that
Slide 3: Post-Close L1 Organization Structure
Global Product Strategy (GPS) Post-Close L1 Organization Structure CEO Europe / Canada / ANZ Commercial Research & Development Technical Operations US Commercial Intercontinental Commercial West. Europe, Cent. Europe, Canada, Australia, NZ 1 EU Immunology EU Hematology Latin America, Eastern Europe
Slide 4: We will strengthen our key governance bodies to enable our new organization
We will strengthen our key governance bodies to enable our new organization ExCo In-line Committee Pipeline Committee Chaired by Head of Global Product Strategy Co-chaired by Head of R&D and Head of Corp Development Future members Key responsibilities Deliver maximum sustainable value of in-line por
Slide 5: New organization: new global capabilities in Commercial
New organization The new organization will transform and create new global capabilities in Commercial Functions Oncology Intercontinental Commercial Europe / Canada / ANZ Commercial 4 US Commercial Global Product Strategy (GPS) 1 International Commercial HAE & LSD Neuroscience & Commercial Excellenc
Slide 6: New organization: new global capabilities in R&D and Operations
New organization The new organization will transform and create new global capabilities in R&D and Operations Research & Development 2 Technical Operations Research & Development Research & Development Finance, Operations, & IT 1 Technical Operations Corporate Development and Public Affairs 1 Operat
Slide 7: New organization: new global capabilities in G&A functions
New organization The new organization will transform and create new global capabilities in G&A functions Legal Compliance Legal Compliance Legal 1 Additional Corporate and Business Services functions, locations, and timing will be forthcoming; Procurement scope to be defined; HR Operations and Finan
Slide 8: Organization Design Timeline
Organization Design Timeline L1 executives - working with CITs - design L2 organization, update job descriptions and define supporting processes Mid April Most L2 appointments made (by L1 executives and approved by CEO) Before close L1 & L2 executives attend leadership summit to discuss strategy, op
Slide 9: Organization Design Timeline
Organization Design Timeline Timing Milestone" Late March Most L1 appointments made (by CEO with Board approval) Mid April L1 executives - working with CITs - design L2 organization, Before close Immediately post close Close thru September update job descriptions and define supporting processes Most